This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2009-0078v1 14/7/645    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Guarneri, V. Articles by Conte, P. Search for Related Content PubMed PubMed Citation Articles by Guarneri, V. Articles by Conte, P.

Breast Cancer

Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena University Hospital, Modena, Italy

Key Words. Metastatic breast cancer • Molecular subtypes • Adjuvant therapy

Correspondence: PierFranco Conte, M.D., Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, University Hospital, via del Pozzo 71, 41100 Modena, Italy. Telephone: 39-059-4223299; Fax: 39-059-4224429; e mail: conte.pierfranco{at}unimore.it

Received April 15, 2009; accepted for publication June 16, 2009; first published online in THE ONCOLOGIST Express on July 16, 2009.

Disclosures: Valentina Guarneri: None; PierFranco Conte: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

In spite of advances in treatment strategies, about 25%–40% of patients with breast cancer still eventually develop metastatic disease that is largely incurable. Treatment goals vary from symptom control to lengthening survival, mainly on the basis of patient age and performance status, tumor biology, site and extent of disease, and prior therapies. In particular, breast cancer molecular characterization allows for the identification of breast cancer subtypes with distinct biological features, a distinct clinical course, and distinct treatment sensitivity.

Endocrine manipulation is the cornerstone of therapy in hormone receptor–positive tumors; anti–human epidermal growth factor receptor (HER)-2 agents are essential in the management of HER-2⁺ tumors; and chemotherapy is the only available option so far for the triple-negative subtype. In each of these subtypes, the more efficacious agents have been progressively incorporated into adjuvant treatment. As a consequence, the choice of the optimal therapeutic strategy for patients with metastatic disease is largely influenced by prior exposure to adjuvant therapies. This review contextualizes the data from clinical trials into different clinical scenarios of metastatic disease, taking into account the molecular subtype and prior adjuvant treatments.